Table 2

Individual exhaled nitric oxide levels before (Pre) and 30 minutes after (Post) inhalation of nebulised saline andl-name during each phase of the study

Patient no.		NO Levels phase 1: l-NAME 54 mg (ppb)		Patient no.
		Histamine					AMP	Histamine				AMP
		Saline						l-NAME				Saline				l-NAME		Saline				l-NAME		Saline		l-NAME
		Pre	Post					Pre	Post			Pre	Post			Pre	Post	Pre	Post			Pre	Post	Pre	Post	Pre	Post
1^2-150	8	3		4	0	6	6	1	0	1^2-150	6	5		4	0		3	5		5	1
2^2-150	21	19		14	4	25	32	30	9	2^2-150	25	21		32	7		37	30		21	4
3^2-150	30	32		32	8	19	20	38	2	3^2-150	21	25		27	3		20	24		23	1
4^2-150	62	103		27	2	44	46	44	1	4^2-150	20	20		21	3
5^2-150	74	52		16	0	49	56	29	3	5^2-150	13	13		7	0
6	19	36		40	2	41	33	23	18	6	16	16		13	4		26	8		12	3
7	24	6		17	2	8	2	33	9	7	22	24		26	3		21	22		31	7
8	21	14		30	2	13	12	40	6	8	13	13		17	2		16	15		15	4
9	78	82		51	51	97	120	120	67	9	7	8		9	2		11	12		12	5
10^2-150	45	49		24	19					10^2-150	26	26		23	9		33	39		47	14
11^2-150	14	13		13	0					11^2-150	11	12		10	1		8	8		5	0
12^2-150	45	33		44	0					12^2-150	13	13		13	2		21	8		13	5
13	17	20		13	0					13							43	43		46	4
14	31	19		14	4
15	46	53		53	10
Mean	36	36		26	7^2-151	34	36	40	13^‡	Mean	16	16		17	3^2-151		22	19		21	5^2-151
95% CI	24 to 48	20 to 51		17 to 34	0 to 14	12 to 56	8 to 64	15 to 65	0 to 29	95% CI	12 to 20	12 to 21		11 to 22	1 to 5		13 to 30	11 to 28		11 to 31	2 to 8

↵2-150 Participated in phases 1 and 2.
↵2-151 p<0.001, ^‡ p<0.005 v baseline (Pre) level.